• Approved for castration-resistant metastatic prostate cancer in line with NICE.
• Approved for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in line with NICE and NHS England Commissioning Policy.

• 60mg tablets
• Approved for treating hormone‑relapsed non‑metastatic prostate cancer that is at high risk of metastasising in adults in line with NICE
• Approved for treating hormone-sensitive metastatic prostate cancer in adults in line with NICE, only if:
  
  • docetaxel is not suitable

Initiate with specialist advice.

• 300mg tablets
• Approved for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease in line with NICE
• Approved with andorgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer in line with NICE and NHSE Specialised Commissioning guidance

• Approved for use in adults with metastatic hormone-relapsed prostate cancer, who have not had chemotherapy in line with NICE.
• Approved for treating hormone-sensitive metastatic prostate cancer in line with NICE